Phase 2a Study of PBTZ169

Summary

Multicenter, open, randomized study with active control (isoniazid) to evaluate the early antibacterial activity, safety and pharmacokinetics of the drug PBTZ169 (capsules 80 mg) when used in patients with first-diagnosed tuberculosis of the respiratory system with bacterial excretion and saved bacterial susceptibility to isoniazid and rifampicin

Timeline

Start

2016-12-16

Primary completion

2017-09-10

Completion

2018-02-22

Outcome

Outcome not reported

Stopped (Enrollment): “Very slow enrollment”

Drugs

Indications